ROCKVILLE, MD - MaxCyte, Inc. (NASDAQ:MXCT; LSE:MXCT), a cell-engineering company focused on providing technologies for cell therapeutics, announced the retirement of Art Mandell from its Board of Directors, effective December 31, 2024. Mandell, who has been a part of the board since 2006, played a significant role in the company's growth, including its initial public offerings on the UK AIM exchange and the US Nasdaq, and the launch of its ExPERT™ platform.
The company credits Mandell for his leadership and contributions that helped position MaxCyte as a leader in cell engineering. Chairman Richard Douglas expressed gratitude for Mandell's "exceptional leadership, scientific insights and valuable contributions." Mandell commented on his departure, stating his pride in the company's achievements and his confidence in MaxCyte's future in providing technology solutions for cell and gene therapies.
MaxCyte's ExPERT™ platform is recognized for supporting the cell therapy market across various stages, from discovery to commercialization. The platform includes a range of instruments, proprietary disposables, and software protocols, backed by a global intellectual property portfolio.
This announcement is based on a press release statement and does not include any forward-looking statements or predictions of future events. The company has not disclosed plans for Mandell's successor or changes to the board's composition following his retirement. MaxCyte continues to focus on advancing cell-based medicines, as evidenced by its strategic platform licenses and support of the industry's first FDA-approved, CRISPR edited non-viral cell therapy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.